PRIME exits® and American Healthcare Capital are pleased to exclusively represent a healthcare company that is revolutionizing the prescription delivery market by providing same-day medication delivery to patients across the United States. The company operates a technology-driven platform that connects hospitals, pharmacies, and patients, ensuring that critical prescriptions are delivered within hours, particularly for recently discharged hospital patients.

Key Achievements and Traction

• Over $100,000 in revenue and profitable

• 50,000+ prescriptions delivered: The Company has successfully delivered over 50,000 prescriptions since its inception, building a reputation for reliability and speed in the market.

• 100+ healthcare partnerships: The company has formed partnerships with over 100 hospitals and pharmacies nationwide, ensuring wide access to its services.

The prescription delivery market is projected to grow at a compound annual growth rate of 17.8%, reaching over $800 million by 2030. Despite this rapid growth, less than 1% of the 6.1 billion prescriptions written annually are currently home delivered, presenting a significant market opportunity. This company is uniquely positioned to capture market share with its patient-centric model, leveraging its proprietary platform to offer real-time tracking, secure packaging, and pharmacist consultations via video.

In 2020, The Company commissioned a third-party evaluation of its intellectual property as it began generating revenue. Using a range of valuation methods, the assessed value ranged from $4.8 million to $64 million. The founder estimates that the current valuation, as reflected on the balance sheet, stands at a minimum of $9.15 million. A detailed third-party valuation report is available upon signing the non-disclosure agreement.

Financial Overview

The Company demonstrates strong growth, with steady year-over-year increases in revenue. In 2024, the company generated $134,482 in total revenues, with a net income of $30,717, putting them on track to gross more than $250,000 by the end of 2025.  For the fiscal year ending December 2023, Balto Rx reported $90,743 in revenues, down from $100,670 in 2022. While the company’s revenues declined slightly from 2022 to 2023, for 2025 is now on track to exceed 2024 revenue.

Deal Structure and Asking Price

With a proven track record, robust technology, and a significant market opportunity, the Company offers a compelling investment opportunity for those looking to enter the fast-growing prescription delivery space. The company is well-positioned to capitalize on the rising demand for home healthcare services and is ready to scale nationwide.

The Company is seeking strategic partners or capital investors to support its next phase of growth. The founder is open to a range of deal structures, including majority equity sales to strategic partners or capital partners, retained and roll over equity. The Company’s valuation considering all the proprietary IPs, solid customer base and drivers is currently at $3,000,000.00. The asking price excludes, cash, accounts receivables, and working capital.